Although IRF8 is linked to favorable outcomes in some cancers, our findings suggest that the IRF8-TAM gene signature predicts immune dysfunction in ovarian cancer, highlighting the complex and context-dependent role of IRF8 within the TME. Here, IRF8 is linked to ovarian carcinoma.